A study developed A33 antibody, which is uniformly expressed in colorectal cancer, positive exosomes loading doxorubicin (Dox) to improve the targeting ability, and this system showed high efficacy for the treatment of colorectal cancer without causing cardiotoxicity. This evidence concerns the gene GPA33 and colorectal cancer.